Capital Flow Monitor · Sponsors · CIK 1956559
Rezo Therapeutics, Inc.
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158 · 415-310-4524
Biotechnology · Corporation· inc. DELAWARE true 2021
Fit score
—
Offering
$80.1M
Sold
$68.1M
% sold
84.9%
Investors
21
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-08-18 | D/A ·current | 506(b) | $80.1M | $68.1M | 84.9% | 21 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Derek Hicks — Executive Officer / Director, SAN FRANCISCO, CA
- Nevan Krogan — Executive Officer / Director, SAN FRANCISCO, CA
-
Vineeta Agarwala — Director, SAN FRANCISCO, CA
3 other raises
- Stipple Bio, Inc. $65.1M of $100.2M · 65.0%
- knownwell, inc. $26.1M of $26.1M · 100.0%
- Thyme Care, Inc. $97.0M of $100.0M · 97.0%
-
Tiba Aynechi — Director, SAN FRANCISCO, CA
1 other raise
- SPRUCE BIOSCIENCES, INC. $50.0M of $50.0M · 100.0%
- Norbert Bischofberger — Director, SAN FRANCISCO, CA
-
Simeon George — Director, SAN FRANCISCO, CA
3 other raises
- SR One Capital Fund III, LP $247.3M of $600.0M · 41.2%
- Avenzo Therapeutics, Inc. $47.2M of $75.0M · 63.0%
- SR One Co-Invest XIII, LLC $0 of —
- George Scangos — Director, SAN FRANCISCO, CA
- Jennifer Chang — Executive Officer, SAN FRANCISCO, CA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.